Drug Interactions between meningococcal conjugate vaccine and ublituximab
This report displays the potential drug interactions for the following 2 drugs:
- meningococcal conjugate vaccine
- ublituximab
Interactions between your drugs
meningococcal conjugate vaccine ublituximab
Applies to: meningococcal conjugate vaccine and ublituximab
MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to patients receiving B-cell depletion therapy with ublituximab has not been studied but may be associated with diminished or suboptimal immunologic response. Ublituximab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered. Pharmacodynamic data has shown the median time to B-cell repletion following discontinuation of ublituximab is 70.3 weeks (range 0.1 to 75.1 weeks). For infants of mothers who have been exposed to ublituximab during pregnancy, there is a potential for depletion of B cells in their infants.
MANAGEMENT: Ublituximab therapy may interfere with the effectiveness of non-live vaccines. Immunization status should be assessed prior to initiating ublituximab and recommended immunizations with non- live vaccines should be completed whenever possible at least 2 weeks prior to ublituximab initiation. For infants of mothers exposed to ublituximab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted. Local vaccination guidelines and prescribing information for individual vaccines should be consulted for further guidance.
References
- (2022) "Product Information. Briumvi (ublituximab)." TG Therapeutics, Inc.
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.